EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision Neuro-Oncology in Glioblastoma: AI-Guided CRISPR Editing and Real-Time Multi-Omics for Genomic Brain Surgery

Matei Șerban, Corneliu Toader, Răzvan-Adrian Covache-Busuioc

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157364 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Matei Șerban und 2 weiteren Autor:innen. Beteiligte Einrichtung: Puls Med Association, 051885 Bucharest, Romania. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Precision Medicine, Genomics. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 295 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy Carol Davila, through the institutional program Publish not Perish.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision neurosurgery is rapidly evolving as a medical specialty by merging genomic medicine, multi-omics technologies, and artificial intelligence (AI) technology, while at the same time, society is shifting away from the traditional, anatomic model of care to consider a more precise, molecular model of care. The general purpose of this review is to contemporaneously reflect on how these advances will impact neurosurgical care by providing us with more precise diagnostic and treatment pathways. We hope to provide a relevant review of the recent advances in genomics and multi-omics in the context of clinical practice and highlight their transformational opportunities in the existing models of care, where improved molecular insights can support improvements in clinical care. More specifically, we will highlight how genomic profiling, CRISPR-Cas9, and multi-omics platforms (genomics, transcriptomics, proteomics, and metabolomics) are increasing our understanding of central nervous system (CNS) disorders. Achievements obtained with transformational technologies such as single-cell RNA sequencing and intraoperative mass spectrometry are exemplary of the molecular diagnostic possibilities in real-time molecular diagnostics to enable a more directed approach in surgical options. We will also explore how identifying specific biomarkers (e.g., IDH mutations and MGMT promoter methylation) became a tipping point in the care of glioblastoma and allowed for the establishment of a new taxonomy of tumors that became applicable for surgeons, where a change in practice enjoined a different surgical resection approach and subsequently stratified the adjuvant therapies undertaken after surgery. Furthermore, we reflect on how the novel genomic characterization of mutations like DEPDC5 and SCN1A transformed the pre-surgery selection of surgical candidates for refractory epilepsy when conventional imaging did not define an epileptogenic zone, thus reducing resective surgery occurring in clinical practice. While we are atop the crest of an exciting wave of advances, we recognize that we also must be diligent about the challenges we must navigate to implement genomic medicine in neurosurgery—including ethical and technical challenges that could arise when genomic mutation-based therapies require the concurrent application of multi-omics data collection to be realized in practice for the benefit of patients, as well as the constraints from the blood–brain barrier. The primary challenges also relate to the possible gene privacy implications around genomic medicine and equitable access to technology-based alternative practice disrupting interventions. We hope the contribution from this review will not just be situational consolidation and integration of knowledge but also a stimulus for new lines of research and clinical practice. We also hope to stimulate mindful discussions about future possibilities for conscientious and sustainable progress in our evolution toward a genomic model of precision neurosurgery. In the spirit of providing a critical perspective, we hope that we are also adding to the larger opportunity to embed molecular precision into neuroscience care, striving to promote better practice and better outcomes for patients in a global sense.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsPrecision MedicineGenomicsCRISPR-Cas SystemsArtificial IntelligenceGene EditingHumansProteomicsMetabolomicsMultiomics

Stichwörter der Autor:innen

CRISPR-Cas9IDH mutationepilepsy surgerygenomic medicineglioblastomamolecular imagingmulti-omicsneurodegenerative diseasesprecision neurosurgerysingle-cell sequencing

Autor:innen und Institutionen

  • Puls Med Association, 051885 Bucharest, Romania.
  • Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Department of Vascular Neurosurgery, National Institute of Neurology and Neurovascular Diseases, 077160 Bucharest, Romania.

Förderung

  • University of Medicine and Pharmacy Carol Davila, through the institutional program Publish not Perish

Zitieren

APA

Șerban, M., Toader, C., & Covache-Busuioc, R. A. (2025). Precision Neuro-Oncology in Glioblastoma: AI-Guided CRISPR Editing and Real-Time Multi-Omics for Genomic Brain Surgery. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157364

Vancouver

Șerban M, Toader C, Covache-Busuioc RA. Precision Neuro-Oncology in Glioblastoma: AI-Guided CRISPR Editing and Real-Time Multi-Omics for Genomic Brain Surgery. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157364

BibTeX
@article{erban2025,
  author = {Șerban, Matei and Toader, Corneliu and Covache-Busuioc, Răzvan-Adrian},
  title = {Precision Neuro-Oncology in Glioblastoma: AI-Guided CRISPR Editing and Real-Time Multi-Omics for Genomic Brain Surgery},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157364}
}
Kostenlos starten →